Cargando…

Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India

BACKGROUND: Favipiravir, an RNA-dependent RNA polymerase inhibitor (RdRp), is a broad-spectrum oral antiviral agent approved in India under emergency use authorization, for the treatment of mild-to-moderate coronavirus disease (COVID-19). The present study was planned to evaluate the effectiveness a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joshi, Shashank, Vora, Agam, Venugopal, K, Dadhich, Pramod, Daxini, Anil, Bhagat, Sagar, Patil, Saiprasad, Barkate, Hanmant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154000/ https://www.ncbi.nlm.nih.gov/pubmed/35656155 http://dx.doi.org/10.2147/POR.S364066

Ejemplares similares

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India
por: Vaswani, Bharat, et al.
Publicado: (2020)

Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
por: Reddy, Pavan Kumar, et al.
Publicado: (2022)

Response to the comments received on article “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
por: Udwadia, Zarir F., et al.
Publicado: (2021)

The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting
por: Vaswani, Bharat, et al.
Publicado: (2021)

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
por: Udwadia, Zarir F., et al.
Publicado: (2021)

Fluticasone Furoate/Vilanterol Use Trends and Characteristics in Patients With Obstructive Airway Disease: A Real-World Study of 10,374 Patients From India
por: Prabhudesai, Prahlad, et al.
Publicado: (2023)

A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients
por: Zirpe, Kapil G, et al.
Publicado: (2021)

The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study
por: Vaswani, Bharat, et al.
Publicado: (2022)

Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review
por: Dhar, Raja, et al.
Publicado: (2022)

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
por: Salvi, Sundeep, et al.
Publicado: (2022)

ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts
por: Dhar, Raja, et al.
Publicado: (2022)

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus
por: Desai, Chirag, et al.
Publicado: (2022)

Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective
por: Vaid, Ashok K., et al.
Publicado: (2020)

ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA)
por: Sahoo, Tarini Prasad, et al.
Publicado: (2023)

Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
por: Salvi, Sundeep, et al.
Publicado: (2021)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Prospective, Open-Label, Multi-Centre, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican™ Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)
por: Parasramani, Srichand G, et al.
Publicado: (2022)

An Open-Label, Randomized, Double-Arm Clinical Trial to Compare the Effectiveness and Safety of Super Bioavailable Itraconazole Capsules and Itraconazole Capsules in the Management of Dermatophytosis in India
por: Shenoy, Manjunath, et al.
Publicado: (2021)

An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India
por: Viswanath, Vishalakshi, et al.
Publicado: (2022)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016)

Management of Dermatophytosis: Real-World Indian Perspective
por: Shenoy, Manjunath, et al.
Publicado: (2023)

Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
por: AlQahtani, Manaf, et al.
Publicado: (2022)

Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study)
por: Kerure, Amit, et al.
Publicado: (2023)

The need for vaccination in adults with chronic (noncommunicable) diseases in India – lessons from around the world
por: Vora, Agam, et al.
Publicado: (2022)

The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study
por: Siripongboonsitti, Taweegrit, et al.
Publicado: (2023)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus
por: Viswanath, Vishalakshi, et al.
Publicado: (2022)

Author Correction: Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
por: AlQahtani, Manaf, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population
por: Barkate, Hanmant, et al.
Publicado: (2018)

Herpes zoster in outpatient departments of healthcare centers in India: a review of literature
por: Patki, Anil, et al.
Publicado: (2021)

Awareness, Attitude, and Current Practices Toward Influenza Vaccination Among Physicians in India: A Multicenter, Cross-Sectional Study
por: Vora, Agam, et al.
Publicado: (2021)

Prospective Efficacy and Safety Study of an Innovative Kerascalp Hair Growth Serum in Mild-to-Moderate Alopecia in India: Regrowth Study
por: Kohli, Malavika, et al.
Publicado: (2023)

Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al.
por: Mori, Nobuaki
Publicado: (2022)

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
por: Solaymani-Dodaran, Masoud, et al.
Publicado: (2021)

Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals()
por: Alamer, Ahmad, et al.
Publicado: (2023)

Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial
por: Adhikari, P., et al.
Publicado: (2022)

Vaccination in Older Adults: An Underutilized Opportunity to Promote Healthy Aging in India
por: Vora, Agam, et al.
Publicado: (2021)

Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
por: Kumar, Pramod, et al.
Publicado: (2021)

Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia – An Observational Real-World Clinical Study
por: Fifer, Simon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ts4njrikcibbe0ijbrlemv2h61